Fig. 3From: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patientsRelationship between overall response rate (ORR) and progression free survival (PFS) in patients with wild-type or mutant (a) KRAS exon 2 and (b) RAS/PIK3CA/BRAF tumorsBack to article page